The BioHub - by Avetix

We were delighted to welcome Simeon George, the CEO and Managing Partner of SR One Capital Management, a global biotech venture capital firm he helped spin out of GSK, onto the BioHub! He’s a physician by training, with an MD from the University of Pennsylvania, an MBA from Wharton, and a background that also includes time at Bain & Company and Goldman Sachs.Over the years, Simeon has helped build and back some of the most impactful companies in modern biotech, including CRISPR Therapeutics, Turning Point Therapeutics, and Principia Biopharma, among many others. He’s also a co-founder and board member of multiple biotech companies, working closely with scientists and founders to bring new medicines to patients

We're joined by Martijn for an engaging discussion on VarmX's latest milestones & the wider biotech market.In Q4 2025, VarmX signed a strategic collaboration with CSL to fully fund a global ph3 trial & pre-launch readiness for their lead asset VMX-C001 - a novel treatment to help restore blood coagulation in patients requiring urgent surgery or experiencing severe bleeding while on FXa DOACs. Martijn shares insight on how the deal came about, what it could mean for patients and VarmX in future, and why CSL are the right partner to develop & deliver VMX-C001 globally.

Today’s guest is Kim Hazen, a seasoned people and culture leader with more than two decades of experience shaping organizations at the intersection of science, business, and talent.Kim is currently the Chief People Officer at Fulcrum Therapeutics, where she leads human resources and culture for a clinical-stage biotech company focused on developing treatments for rare genetic diseases. Over the course of her career, she’s built and scaled people strategies across both life sciences and financial services, holding senior HR leadership roles at organizations like the Broad Institute of MIT and Harvard, Warp Drive Bio, Aegerion Pharmaceuticals, and several major financial institutions.In this we discuss:Kim's 8.5 year journey so far at Fulcrum, from a small, ambitious biotech to the more mature, resilient organization it is today.Restructuring and the lessons learnt about leadership,communication, and empathy during times of crisisKim's new book 'The Culture Shock'

In this episode of The BioHub, I’m joined by Rodolphe Clerval, CEO of Coave Therapeutics.Rodolphe’s journey into the CEO seat wasn’t a traditional one. He moved from science into investment banking, then into major business development roles, before stepping into leadership at multiple biotech companies.We talk about that unconventional path, the story behind Coave’s evolution and rebrand, and why their precision gene therapy approach is so exciting. It’s a thoughtful conversation about mindset, leadership, and what it really takes to build in small biotech.

We were delighted to be joined by Kevin Pojasek who's the President and CEO of Enara Bio.Enara Bio is shining a light on Dark Antigen and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients with solid tumors. There pioneering EDAPT® platform enables us to discover cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing library of Dark Antigens that can address the need for novel, cancer-specific targets in solid tumors.In this we cover: The spark that led to the founding of Enara BioEnara's platform EDAPT® and how it finds dark antigens in tumors.Where the field of T-Cell therapy for solid tumors is today.The importance of culture in early stage biotech, and how the company has been built around putting people first.The next major milestones for Enara Bio.

JPM Special — Maureen Hillenmeyer, CEO & Founder of Hexagon BioIn this JPM Special episode of The BioHub, I’m joined by Maureen Hillenmeyer, CEO and Founder of Hexagon Bio.Maureen has built Hexagon around a bold idea: using genomics, computation, and the biology of natural products to unlock entirely new medicines. At JPM, we sat down to talk about what it really takes to build a platform company in today’s market — from scientific conviction and capital discipline to leadership, culture, and long-term vision.We also discuss:What makes Hexagon’s approach fundamentally differentHow Maureen thinks about risk, focus, and scale as a founder-CEOThe realities of building biotech through multiple market cyclesA thoughtful, grounded conversation with one of the most impressive founders in the space.

I’m here with Mike Exton, the CEO of LexiconPharmaceuticals.Mike joined Lexicon in 2024 after two decades of leadershipacross Novartis and Eli Lilly, where he helped launch some of the biggest cardiovascular drugs in the world — including Entresto.Now he’s leading Lexicon through a bold new chapter, with agenomics-driven pipeline focused on cardiometabolism and neuroscience, and a strategy built around delivering best-in-class or first-in-class medicines in areas of real unmet need.Mike, great to have you here

In our first JPM Special 2026, we’re joined by Dirk Thye, CEO of Quince Therapeutics, as the company approaches a defining Phase 3 readout. A candid conversation about high-stakes data, leadership under pressure, and what a true do-or-die moment looks like in biotech.

Today’s guest is Kevin Marks, a biotech entrepreneur and the founder and CEO of Delphia Therapeutics. Kevin has spent his career at the forefront of cancer drug discovery, working across research, strategy, and company building with a singular focus on translating breakthrough science into meaningful medicines for patients. Before founding Delphia, he built deep experience in oncology and precision medicine, helping advance novel therapeutic programs and navigating the complex path from early discovery to clinical development. At Delphia Therapeutics, Kevin is leading the development of a new approach to precision oncology known as activation lethality—an emerging strategy designed to uncover previously untapped cancer vulnerabilities and deliver more targeted, effective treatments. With a background that blends rigorous science, entrepreneurial leadership, and a patient-first mindset, Kevin brings a thoughtful perspective on the future of cancer therapy, innovation in biotech, and what it truly takes to build a science-driven company from the ground up. We’re excited to have him with us today.

On this episode we're joined by Invivo Partners' Gemma Guinart, for a discussion into early-stage biotech investing.Invivo Partners look to invest in compelling in-vivo proof of concept data, and back founding teams across Europe with pre-seed to Series A investment - recent investments from their third fund include Neumirna Tx & Signadori Bio.Tune in to hear more about how Gemma & the team identify investment opportunities & why they focus on early-stage investments in a market that has recently leaned toward late-stage de-risked assets.We also chat briefly through some potential pitfalls for founders looking for funding, their newest fund bridging healthcare & AI, and success stories from the Invivo Partners portfolio, including EsoBiotec.